Evidence map›Paper›PMID 37491432›Full record

SynthesisProstate cancer and prostatic diseases2024

Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs).

Rossella Nicoletti, Andrea Alberti, Daniele Castellani, Chi Hang Yee, Kai Zhang, Darren M C Poon, Peter Ka-Fung Chiu, Riccardo Campi, Giulio Raffaele Resta, Edoardo Dibilio and 11 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Irreversible electroporation as a focal therapy for localized prostate cancer: A systematic review.Indian journal of urology : IJU : journal of the Urological Society of India
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 4 countries.

Rossella Nicoletti *Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.ORCID 0000-0001-6898-7698
Andrea Alberti *Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
Daniele CastellaniUrology Division, Azienda Ospedaliero-Universitaria delle Marche, Università Politecnica delle Marche, Ancona, Italy.
Chi Hang YeeS.H.Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0001-6557-3107
Kai ZhangDepartment of Urology, Beijing United Family Hospital and Clinics, 100015, Beijing, China.
Darren M C PoonComprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Peter Ka-Fung ChiuS.H.Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0002-1499-8372
Riccardo CampiUnit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.ORCID 0000-0001-5237-0888
Giulio Raffaele RestaUnit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
Edoardo DibilioUnit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
Giacomo Maria PirolaUrology Unit, San Giuseppe Hospital, Multimedica Group, Milan, Italy.ORCID 0000-0002-4209-8670
Giuseppe ChiacchioFaculty of Medicine and Surgery, School of Urology, Università Politecnica delle Marche, Ancona, Italy.ORCID 0000-0002-8821-8201
Demetra FuligniFaculty of Medicine and Surgery, School of Urology, Università Politecnica delle Marche, Ancona, Italy.ORCID 0000-0002-4234-0690
Carlo BroccaFaculty of Medicine and Surgery, School of Urology, Università Politecnica delle Marche, Ancona, Italy.
Carlo GiulioniFaculty of Medicine and Surgery, School of Urology, Università Politecnica delle Marche, Ancona, Italy.ORCID 0000-0001-9934-4011
Virgilio De StefanoFaculty of Medicine and Surgery, School of Urology, Università Politecnica delle Marche, Ancona, Italy.
Sergio SerniUnit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
Vineet GauharNg Teng Fong General Hospital (NUHS), Singapore, Singapore.ORCID 0000-0002-3740-7141
Chi Fai NgS.H.Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0002-1723-9646
Mauro GacciUnit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
Jeremy Yuen Chun TeohS.H.Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. jeremyteoh@surgery.cuhk.edu.hk.ORCID 0000-0002-9361-2342
Chinese University of Hong Kong · HKMarche Polytechnic University · ITUniversity of Florence · ITBeijing United Family Hospital · CNMultiMedica · ITNg Teng Fong General Hospital · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFocal therapy (FT) is a promising alternative with curative intent for Low- to Intermediate-risk localized Prostate Cancer (PCa), claiming better functional outcomes and safety profile than standard whole-gland treatments. Ten different FT modalities have been described in the literature. The objective of our narrative review is to evaluate the safety profile and functional outcomes of these different modalities and the current most used tools of assessment for those outcomes. MATERIAL AND

methodsLiterature search was performed on 21st February 2023 using PubMed, EMBASE, and Scopus, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA). Articles reporting whole-gland treatments were excluded. All articles reporting functional outcomes were included.

resultsOne-hundred-seven studies, reporting data on 6933 patients, were included (26 on High Intensity Focal Ultrasound, 22 on Focal Cryotherapy, 14 on Irreversible Electroporation, 11 on Focal brachytherapy, 10 on Focal Laser Ablation, 8 on Photodynamic Therapy, 3 on Microwave ablation, 3 on Robotic Partial Prostatectomy, 2 on bipolar Radio Frequency Ablation, 1 on Prostatic Artery Embolization, and 7 studies comparing different FTs). Post-operative pad-free rate ranged between 92.3-100%. Greater heterogeneity exists considering the Change in Erectile Function, with Changing in Erectile function- rates ranging between 0-94.4% (Cryotherapy). The most used Patient-Reported Outcome Measures (PROMs) were the International Prostate Symptom Score and the International Index of Erectile Function for incontinence/urinary function and potency, respectively. The most common reported complications were hematuria, infections, and urethral strictures, with rates widely ranging among different treatments. The Clavien-Dindo Classification was the most used (40/88 papers) to describe adverse events.

conclusionFT is a promising treatment for localized PCa, achieving excellent results in terms of safety and functional outcomes. There is a wide heterogeneity in the definition of PROMS and time of collection between studies. High quality comparative studies with standard treatments are needed to reinforce these findings.

Indexed as

Patient Reported Outcome MeasuresProstatic NeoplasmsBrachytherapyHumansMaleProstatectomyQuality of LifeTreatment Outcome

Identifiers

PMID37491432
OpenAlexW4385231573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.